Clinical Performance of a Phakic Intraocular Lens (IOL)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-20

Study Completion Date

2019-07-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the clinical performance of a phakic intraocular lens (IOL) for the improvement of Uncorrected Near Visual Acuity (UCNVA) in subjects who require between +1.00 and +2.50 Reading Add.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Low-add Multifocal vs. Monofocal IOLs

NCT03749161

Cataract

UNKNOWN NA

Visual Outcomes After Presbyopic Lens Exchange

NCT03790592

Presbyopia

COMPLETED NA

Study on Visual Performance of a Monofocal Intraocular Lens

NCT04740788

Cataract Senile

COMPLETED

Evaluation of Long-Term Clinical Acceptability and Satisfaction With the IC-8 Intraocular Lens

NCT03314766

Cataract Presbyopia

COMPLETED

Presbyopic Phakic Intraocular Lens for Myopia Correction

NCT03836898

Presbyopia Myopia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, open-labeled, multi-site evaluation of clinical performance of the STAAR EVO+ Visian™ Implantable Collamer® Lens (VICL) with Aspheric (EDOF) Optic \[EDOF ICL\] for the improvement of UCNVA in subjects who require between +1.00 and +2.50 Reading Add.

Approximately 48 subjects who meet all eligibility criteria will undergo EDOF ICL implantation in both eyes. All eyes will be followed for 6 months after surgery.

The first eye implanted with the study lens and the appropriate time for fellow eye implantation will be determined by the medical judgement of the Investigator. All eyes will be analyzed for safety and performance.

The primary performance endpoint is defined as achievement of monocular UCNVA of Snellen equivalent 20/40 or better at 40 cm at 6 months after implantation in equal to or greater than 75% of implanted eyes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Presbyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Device: Open label, all subjects receive same treatment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study population

EDOF ICL implanted into both eyes of eligible subjects.

Group Type EXPERIMENTAL

EDOF ICL

Intervention Type DEVICE

The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EDOF ICL

The Visian ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens. It offers an intraocular alternative for the correction of refractive error in those who currently utilize spectacle and/or contact lenses correction.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EVO+ Visian ICL with Aspheric (EDOF) Optic

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must be able to read, understand and provide written informed consent,
2. Willing and able to comply with all treatment and follow-up study related procedures,
3. 40 - 60 years of age at time of surgery if require spherical lens powers from -0.50 D to -18.00 D,
4. 35 - 45 years of age at time of surgery if require a spherical lens power from 0.0 D to +3.00 D,
5. Preoperative refraction fully correctable with available lens powers, with ≤ 0.75 D preoperative refractive and residual cylinder,
6. \< 0.75 D spherical equivalent difference between cycloplegic and manifest refractions,
7. Stable correction (± 0.50 D) as determined by manifest refraction spherical equivalent (MRSE),
8. Best Corrected Distance Visual Acuity 20/20 or better in both eyes,
9. Requires +1.00 D to +2.50 D reading add,
10. Anterior chamber depth (ACD) ≥ 2.8 mm if require spherical lens powers from -0.50 D to -18.00 D,
11. ACD ≥ 3.0 mm if require spherical lens powers from 0.00 D to +3.00 D,
12. Anterior chamber angle ≥ Grade III,
13. Phakic in both eyes,
14. Current contact lens wearers need to demonstrate a stable refraction, (± 0.5 D), expressed as MRSE, on two consecutive examination dates with refractive stability determined by the following criteria:

1. contact lenses were not worn for at least 2 weeks (rigid and toric contact lenses) or 3 days (soft contact lenses) prior to the first refraction,
2. two refractions were performed at least 7 days apart.

Exclusion Criteria

1. Participation in a clinical trial within 30 days prior to entry into this study and/or during the period of study participation,
2. Previous intraocular or corneal surgery in either eye, including refractive surgery,
3. Progressive sight threatening disease or other previous or current ocular conditions, other than myopia in either eye,
4. Low/abnormal corneal endothelial cell density,
5. Amblyopia,
6. Presence of active or history of chronic inflammation in either eye,
7. Clinically significant irregular astigmatism in either eye,
8. Serious, acute, chronic or systemic, non-ophthalmic disease or illness that would increase the operative risk, confound the outcome(s) of the study or which may preclude study completion,
9. Use of topical steroids at time of implantation,
10. Systemic or topical medication, other than prescribed study medications that may confound the outcome or increase the risk to the subject,
11. Allergy to anesthetics or other postoperative medications required in this study,
12. Subject who is pregnant, plans to become pregnant, or is lactating during the course of the study, or has another condition associated with the fluctuation of hormones that could lead to refractive changes,
13. Subjects who present any emotional, physiologic, or anatomical condition which may preclude study participation.

Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No